Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Intradigm licenses key RNAi Intellectual Property from University of Massachusetts Medical School

Intradigm : 10 April, 2008  (Company News)
Intradigm has licensed key intellectual property (IP) that covers certain efficacy-enhancing structural elements of small interfering RNA (siRNA) from the University of Massachusetts Medical School.
The licensed IP includes parameters for the structural modifications for next generation siRNAs including the ‘Zamore Design Rules’ that significantly improve the potency and efficacy of RNAi therapeutics. The licensed technology allows Intradigm to incorporate novel siRNA sequences into the company's proprietary RNAi delivery systems to create potent and effective siRNA therapeutics.

The technology licensed from the University of Massachusetts Medical School provides Intradigm with a strong IP position around structural features for a next generation of siRNA molecules. Additionally, Intradigm also possesses a strong IP position surrounding biodegradable polycationic polymers for the delivery of RNAi therapeutics which the company further strengthened through its recent licensing of complementary technology from the Massachusetts Institute of Technology (MIT). This newly licensed RNAi IP estate, combined with Intradigm's innovative delivery technology and proprietary siRNA sequences, positions the company as a leader in the RNAi therapeutic space.

'By licensing this important IP from the University of Massachusetts Medical School, which we believe to be the clear center of excellence for breakthrough siRNA academic research, Intradigm has taken another critical step toward its goal of establishing itself as a leader in the development and commercialization of novel RNAi therapeutics,' said Mohammad Azab, MD, president and chief executive officer of Intradigm. 'We have established an impressive IP portfolio that spans the areas of siRNA structure and sequence, as well as RNAi delivery, providing us a distinct competitive advantage enjoyed by very few other companies.'

'We are keenly aware of the critical role that the fundamental RNAi research being conducted in our labs may play in ultimately bringing novel RNAi therapeutics to patients who desperately need them,' stated James P McNamara, PhD, executive director of the office of technology management at the University of Massachusetts Medical School. 'For this reason, we are driven to align with leaders in the RNAi therapeutic space, such as Intradigm, to provide them access to our intellectual property and support their important drug development efforts. We are eager to witness Intradigm's progress and excited at that prospect of our IP playing a central role in the company's future success.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo